|
Vaccine Detail
Poly Microsphere Encapsulated HER2/neu Oral Vaccine |
Vaccine Information |
- Vaccine Name: Poly Microsphere Encapsulated HER2/neu Oral Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007034
- Type: Multipeptide vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: ERBB2
- ERBB2
gene engineering:
- Type: Recombinant protein preparation
- Description: (Lee et al., 2018)
- Detailed Gene Information: Click Here.
- Preparation: Herceptin was chemically conjugated to the SPION-encapsulating PLGA nanoparticles to target the human epidermal growth factor receptor 2 (Her2/neu) overexpressing breast cancers (Lee et al., 2018).
- Description: This is for Breast cancer and Ovarian Cancer (NCT02795988). A cancer vaccine consisting of Her2/neu peptides incorporated into microspheres of poly (lactide-co-glycolide) (PLGA), a biodegradable polymer. Poly microsphere encapsulated HER2/neu oral vaccine has been investigated for use in immunotherapy for tumors positive for HER-2/neu, a tumor associated antigen that is overexpressed in various cancers, including breast and ovarian cancer (Lee et al., 2018; NCIT_C2718).
|
Host Response |
|
References |
Lee et al., 2018: Lee SJ, Kim HJ, Huh YM, Kim IW, Jeong JH, Kim JC, Kim JD. Functionalized Magnetic PLGA Nanospheres for Targeting and Bioimaging of Breast Cancer. Journal of nanoscience and nanotechnology. 2018; 18(3); 1542-1547. [PubMed: 29448628].
NCIT_C2718: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2718]
NCT02795988: [https://clinicaltrials.gov/ct2/show/NCT02795988]
|
|